Ignite Creation Date:
2025-12-25 @ 3:33 AM
Ignite Modification Date:
2026-02-23 @ 12:23 PM
Study NCT ID:
NCT02606305
Status:
COMPLETED
Last Update Posted:
2024-06-14
First Post:
2015-11-06
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRĪ±) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
Sponsor:
ImmunoGen, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Epithelial ovarian cancer | View |
| None | Fallopian tube cancer | View |
| None | Primary peritoneal cancer | View |
| None | IMGN853 | View |
| None | ADC | View |
| None | Antibody drug conjugate | View |
| None | ImmunoGen | View |
| None | Antibody | View |
| None | Phase 1 | View |
| None | Folate receptor alpha | View |
| None | Mirvetuximab | View |